PuraPharm Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

PuraPharm şirketinin toplam hissedar öz sermayesi HK$130.5M ve toplam borcu HK$377.7M olup, bu da borç-öz sermaye oranını 289.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla HK$781.7M ve HK$651.3M dir.

Anahtar bilgiler

289.5%

Borç/özkaynak oranı

HK$377.70m

Borç

Faiz karşılama oranı	n/a
Nakit	HK$51.09m
Eşitlik	HK$130.47m
Toplam yükümlülükler	HK$651.26m
Toplam varlıklar	HK$781.73m

Son finansal sağlık güncellemeleri

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

Is PuraPharm (HKG:1498) A Risky Investment?

Sep 28

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Nov 02

Is PuraPharm (HKG:1498) A Risky Investment?

Aug 23

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Apr 01

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

Dec 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1498 'nin kısa vadeli varlıkları ( HK$305.7M ) kısa vadeli yükümlülüklerini ( HK$510.2M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 1498 şirketinin kısa vadeli varlıkları ( HK$305.7M ) uzun vadeli yükümlülüklerini ( HK$141.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1498 'nin net borç/öz sermaye oranı ( 250.3% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 1498 şirketinin borç/öz sermaye oranı son 5 yılda 95% seviyesinden 289.5% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan 1498 mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: 1498 kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 12.3 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

PuraPharm Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is PuraPharm (HKG:1498) A Risky Investment?

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

Is PuraPharm (HKG:1498) A Risky Investment?

Recent updates

First half 2024 earnings released: HK$0.047 loss per share (vs HK$0.095 loss in 1H 2023)

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin